- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02286700
Skin Effects of a Topical Amino Acid Moisturizing Cream and Desonide in Atopic Dermatitis
November 10, 2014 updated by: NeoStrata Company, Inc.
A Randomized, Double-Blind, Active Control, 5 Week Study to Evaluate the Safety and Skin Effects of A New, Twice-daily, Topically Applied Amino Acid Moisturizing Cream vs. Desonide Cream in Adult Atopic Dermatitis
The purpose of this study is to compare the effects of an amino acid moisturizing cream and desonide cream in reducing skin symptoms associated with AD/eczema in subjects with mild to moderate atopic dermatitis/eczema.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
This is a double-blind, randomized study comparing the effects of an amino acid moisturizing cream and desonide cream in reducing skin symptoms associated with AD/eczema in subjects with mild to moderate atopic dermatitis/eczema.
Atopic dermatitis (AD), also known as Eczema, is a chronic inflammatory skin disease that most commonly affects infants and children with a prevalence of 10-20% in children as compared to 1-3% in adults.
Patients with AD have dry, irritated skin and often experience severe pruritus.
Treatment of AD involves avoidance of triggers and infectious agents, cutaneous hydration, control of pruritus, and anti-inflammatory agents.
Topical calcineurin inhibitors and steroids are commonly used prescription anti-inflammatory treatments.
Unfortunately, there are potential side effects of long-term topical glucocorticoid use including skin atrophy, development of striae, perioral dermatitis, acne, and even hypothalamic-pituitary-adrenal axis suppression.
However, many moisturizers are available without a prescription to soothe skin and reduce symptoms associated with AD/eczema via increased hydration, improved barrier function and anti-irritancy effects.
The study cream being compared to desonide is a cosmetic moisturizing formulation that contains a cosmetic amino acid dipeptide (e.g., contains 2 amino acids).
This study is being conducted to understand the benefits of the amino acid dipeptide moisturizing cream versus dermatologist-prescribed desonide cream in reducing the symptoms associated with AD/eczema in order to evaluate its potential use in the eczema care market.
For this study, approximately 60 males and females, 18 years of age and older, who are in general good health, but diagnosed with mild to moderate AD/eczema, will be recruited, screened, and fully consented, with the goal of enrolling up to 42 evaluable subjects.
The 42 Subjects (21 subjects per group) will be randomly and equally assigned to either one of 2 treatment groups of amino acid moisturizing cream or desonide cream.
Neither study subjects nor study staff will be aware of the treatment assigned.
The subjects will be asked to participate for approximately 5 weeks, over 5 study visits: Screening/Baseline, Weeks 1-3 (Treatment Period), Regression weeks 4 & 5.
Each subject will receive one, 15 gram, blinded study cream at each treatment visit to apply twice daily at home for 3 weeks; a 2-week regression phase of no study cream will follow the treatment phase.
A predetermined target lesion will be assessed at each time point via established clinical grading scales including: Target lesion Atopic Dermatitis Severity Index (TADSI), Eczema Area Severity Index (EASI), Static IGA of targeted lesion, Total IGA (PGA) and Body Surface Area involvement.
All grading will be completed by the principal or sub-investigators.
Photographs will also be taken at each time point to assess changes during the treatment and regression phases.
Other established scales will be utilized to collect patient perception of skin effects such as: Patient-Oriented Eczema Measure (POEM), subjects' assessment of pruritus (VAS); a self-assessment questionnaire will be utilized to collect information on perceived benefits and product aesthetics.
This study has been IRB approved and is scheduled to begin November of 2014 at Massachusetts General Hospital, specifically at the Clinical Unit for Research Trials in Skin (CURTIS) under principal investigator, Alexandra B. Kimball, MD.
The study is being sponsored by NeoStrata Company, Inc, Princeton, NJ.
Study Type
Interventional
Enrollment (Anticipated)
42
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Barbara A. Green, RPh
- Phone Number: 609-986-2971
- Email: bgreen@neostrata.com
Study Contact Backup
- Name: Justine K. Gostomski, MS
- Phone Number: 609-986-2969
- Email: jgostomski@neostrata.com
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Mass General Hospital: Clinical Unit for Research Trials in Skin
-
Contact:
- Lynne Hermosilla
- Phone Number: 617-725-5066
- Email: harvardskinstudies@partners.org
-
Principal Investigator:
- Alexandra B Kimball, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female subjects in general good health 18 years of age or older
- Diagnosis of atopic dermatitis will be made based on clinical criteria. Each patient must have at least one eczematous target lesion with area ranging from 10-500 cm2 of mild to moderate severity with a grade of at least 6 on the TADSI scale, plus presence of itch
- Body surface area affected by AD lesions: ≤ 5% at start of treatment
Exclusion Criteria:
- Pregnancy or breastfeeding
- Any condition or therapy that in the investigator's opinion may pose a risk to the subject or that could interfere with any evaluation in the study
- Widespread AD requiring systemic therapy
- Diagnosis of allergic contact dermatitis
- Known hypersensitivity to any of the constituents or excipients of the investigational product
- Diagnosed with immunocompromised status
- Use of systemic AD therapy, e.g. systemic corticosteroids, cyclosporine A, azathioprine, mycophenolate mofetil, or phototherapy in the past 1 month.
- Use of phototherapy in the past 2 weeks
- Use of any topical AD therapy such as corticosteroids or topical immunomodulators in the past 2 weeks
- Use of local anti-itch or medical device treatments, e.g. benadryl, atopiclair, epiceram in the past 2 weeks
- Use of topical moisturizers less than 24 hours in advance of the baseline visit on eczema lesions
- Participation in another clinical research study with an investigational drug within 4 weeks before randomization in this study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Desonide Group
Group randomly receiving desonide cream as the treatment cream for 3 weeks.
Fifteen (15) gram tubes are dispensed at the beginning of each week and will be applied twice daily, by the subject, during the 3 week treatment phase.
|
Study cream randomized and distributed to subjects, applied twice daily for 3 weeks and evaluated ability to reduce atopic dermatitis symptoms.
Other Names:
|
Experimental: Amino Acid Group
Group randomly receiving amino acid moisturizing cream as the treatment cream for 3 weeks.
Fifteen (15) gram tubes are dispensed at the beginning of each week and will be applied twice daily, by the subject, during the 3 week treatment phase.
|
Study cream randomized and distributed to subjects, applied twice daily for 3 weeks and evaluated ability to reduce atopic dermatitis symptoms.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in skin effects of an amino acid moisturizing cream and desonide cream in reducing skin symptoms associated with AD/eczema in subjects with mild to moderate atopic dermatitis/eczema.
Time Frame: 5 weeks
|
Change in erythema, pruritus, exudation, excoriation and Lichenification from baseline of atopic dermatitis target lesions after application of either amino acid moisturizing cream or desonide cream twice daily for three weeks.
|
5 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Alexandra Kimball, MD, Massachusetts General Hospital: Clinical Unit for Research Trials in Skin
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Leung DM, Eichenfield LF, Boguniewicz M. Chapter 14. Atopic Dermatitis (Atopic Eczema). In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K. eds. Fitzpatrick's Dermatology in General Medicine, 8e. New York, NY: McGraw-Hill; 2012. http://accessmedicine.mhmedical.com/content.aspx?bookid=392&Sectionid=41138709. Accessed July 03, 2014.
- Elias PM, Steinhoff M. "Outside-to-inside" (and now back to "outside") pathogenic mechanisms in atopic dermatitis. J Invest Dermatol. 2008 May;128(5):1067-70. doi: 10.1038/jid.2008.88.
- Williams HC. Clinical practice. Atopic dermatitis. N Engl J Med. 2005 Jun 2;352(22):2314-24. doi: 10.1056/NEJMcp042803. No abstract available.
- Rudikoff D, Lebwohl M. Atopic dermatitis. Lancet. 1998 Jun 6;351(9117):1715-21. doi: 10.1016/S0140-6736(97)12082-7. No abstract available.
- Langan SM, Williams HC. What causes worsening of eczema? A systematic review. Br J Dermatol. 2006 Sep;155(3):504-14. doi: 10.1111/j.1365-2133.2006.07381.x.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2014
Primary Completion (Anticipated)
February 1, 2015
Study Completion (Anticipated)
March 1, 2015
Study Registration Dates
First Submitted
November 4, 2014
First Submitted That Met QC Criteria
November 5, 2014
First Posted (Estimate)
November 10, 2014
Study Record Updates
Last Update Posted (Estimate)
November 11, 2014
Last Update Submitted That Met QC Criteria
November 10, 2014
Last Verified
November 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 14-ECD108
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Eczema
-
Technical University of MunichCelgene CorporationCompletedEczema | Nummular Eczema | Dermatitis Eczema | Nummular DermatitisGermany
-
Odense University HospitalCompletedVesicular Palmoplantar Eczema | PompholyxDenmark
-
Gary GoldenbergCompletedHand Eczema | Foot EczemaUnited States
-
University Hospitals Coventry and Warwickshire...University of WarwickNot yet recruitingCancer | Skin Cancer | Dry Skin; Eczema | Medical Device Site EczemaUnited Kingdom
-
Zealand University HospitalUniversity of Copenhagen; Danish Working Environment FundCompleted
-
SalvatCompleted
-
University Hospital Bispebjerg and FrederiksbergStatens Serum InstitutRecruiting
-
BayerCompleted
-
Cosmetique Active InternationalCompleted
Clinical Trials on Desonide Cream
-
Procter & Gamble BeautyCompletedEczema | Dermatitis, AtopicUnited States
-
Procter and GambleCompleted
-
Pierre Fabre MedicamentCompletedAtopic DermatitisEstonia, France, Lithuania, Poland, Romania
-
Promius Pharma, LLCCompletedAtopic DermatitisUnited States
-
Wake Forest UniversityCompletedAtopic DermatitisUnited States
-
MC2 TherapeuticsCompleted
-
University of North Carolina, CharlotteTeva Branded Pharmaceutical Products R&D, Inc.CompletedMultiple SclerosisUnited States
-
Incyte CorporationCompletedCutaneous Lichen PlanusUnited States, Canada
-
Incyte CorporationRecruitingPrurigoUnited States, Spain, France, Poland, Germany, Belgium, Netherlands, Argentina, Italy, Canada, Chile, Brazil